US Patent 10214586 PD-L1 antibodies
Patent 10214586 was granted and assigned to Eli Lilly and Company on February, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+252 characters)
Article
Patent abstract
The present invention relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics.
Edits on 11 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 5 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 2 Oct, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
Dale Lincoln Ludwig0
Juqun Shen0
Marshall Davenport Snavely0
Vera Molkenthin0
Yiwen Li0
Edits on 13 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 30 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
102145860
Date of Patent
February 26, 2019
0Patent Application Number
152399590
Date Filed
August 18, 2016
0Patent Citations Received
Patent Primary Examiner
Edits on 2 Feb, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 25 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10214586 PD-L1 antibodies
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10214586
Date of patent
February 26, 2019
Patent application number
15239959
Date Filed
August 18, 2016
Patent primary examiner
Find more entities like US Patent 10214586 PD-L1 antibodies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
